mHealth can reduce costs in some areas of health care
Citation: Iribarren SJ, Cato K, Falzon L, et al. What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions. PLOS One 2017; 12: e0170581
What is this? The COVID-19 pandemic is placing a strain on healthcare systems. Existing research on the cost effectiveness of mobile health (mHealth) to deliver health care may provide useful information for policy makers.
In this systematic review, the authors searched for research that evaluated the costs and outcomes of mHealth (including the use of mobile phones, patient monitoring devices, personal digital assistants and other wireless devices to support medical and public health practice). They restricted their search to studies published in English up to April 2016. They included 39 economic evaluations assessing mHealth for behavior change communication (27 studies), data collection (7) and service delivery (5). Most (34) of the included studies were from upper and upper-middle income countries.
What was found: mHealth, either as a primary intervention or as a component of an intervention, can be economically beneficial and reduce costs.
Text messaging and apps are effective platforms for delivering mHealth.
Disease detection and point-of-care testing using mobile devices have high potential for increasing access to testing and can be cost-effective.
The economic effects of mHealth in low and low-middle income countries are uncertain.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.